Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate

References

• National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH consensus statement. 2000;17:1–45
   Google Scholar
• National Osteoporosis Foundation. America’s bone health: the state of osteoporosis and low bone mass in our nation. 2002
   Google Scholar
• Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120–6
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189–99
   PubMed Web of Science ®Google Scholar
• Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965–8
   PubMed Web of Science ®Google Scholar
• Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 2003;72:408 [abstract P–297]
   Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   Google Scholar
• Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951–65
   PubMed Web of Science ®Google Scholar
• Mersfelder T, Armitstead JA, Ivey MF, et al. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manage Q 1999;18:50–8
   PubMedGoogle Scholar
• Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Min Res 2001;15:S529 [abstract M406]
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Ettinger M, Gallagher R, Amonkar M, et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 2004;50:S513
   Web of Science ®Google Scholar
• US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004
   Google Scholar
• Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Exp Opin Drug Saf 2002;1:71–8
   PubMedGoogle Scholar
• Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377–82
   Google Scholar
• Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14: 259–62
   Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–16
   PubMed Web of Science ®Google Scholar
• Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002;55:809–17
   PubMed Web of Science ®Google Scholar
• Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003;21:153–8
   PubMed Web of Science ®Google Scholar
• Gold DT, Ettinger M, Gallagher R, et al. Medication burden among women with postmenopausal osteoporosis. Presented at the National Osteoporosis Foundation 6th International Symposium, Washington, DC, 6–10 April 2005
   Google Scholar
• Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117–23
   Google Scholar
• Schaffer SD, Yoon SJ. Evidence-based methods to enhance medication adherence. Nurse Pract 2001;26:44–54
   PubMedGoogle Scholar
• Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9:S66–80
   Google Scholar
• Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97–106
   PubMed Web of Science ®Google Scholar
• van Beek E, Hoekstra M, van de Ruit M, et al. Structural requirements for bisphosphonate actions in vitro. J Bone Min Res 1994;9:1875–82
   PubMed Web of Science ®Google Scholar
• Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Min Res 1999;14:53–65
   PubMed Web of Science ®Google Scholar
• Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Min Res 1991;6: 1003–11
   Google Scholar
• Bauss F, Endele R, Besenfelder E, et al. Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection. Calcif Tissue Int 2002;70:289–90 [abstract P–128]
   Google Scholar
• Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423–33
   PubMed Web of Science ®Google Scholar
• Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002;30:320–4
   Google Scholar
• Bauss F, Lalla S, Endele R, et al. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheum 2002;29:2200–8
   PubMed Web of Science ®Google Scholar
• Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Min Res 2001;16:1871–8
   PubMed Web of Science ®Google Scholar
• Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15: 792–8
   Google Scholar
• McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Min Res 2004;19:11–8
   PubMed Web of Science ®Google Scholar
• Lewiecki M, Zaidi M, Drezner M, et al. Intermittent intravenous ibandronate injections are at least as effective as daily oral ibandronate: 1-year DIVA results. Menopause 2005;12:802
   Web of Science ®Google Scholar
• Delmas PD, Emkey R, Gilbride J, et al. Oral ibandronate has a similar gastrointestinal (GI) safety profile to placebo in patients with a history of GI disorders or receiving concomitant NSAIDS. Osteoporos Int 2003;14:S74 [abstract P267]
   Google Scholar
• Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14:158–70
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7: 377–87
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281–9
   PubMed Web of Science ®Google Scholar
• Janssen van Doorn K, Neyns B, Van der Niepen P, et al. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron 2001;89:467–8
   PubMed Web of Science ®Google Scholar
• Recker RR, Weinstein RS, Chesnut CH 3rd, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004;15: 231–7
   Google Scholar
• Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133–7
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Min Res 2004;19:1241–9
   Google Scholar
• Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 2003;25:19–34
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Min Res 2005;20: 1315–22
   PubMed Web of Science ®Google Scholar
• Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006;65:654–61 [Epub 8 Dec 2005]
   Google Scholar
• Delmas P, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year results from the DIVA study. Arthritis Rheum 2006 [in press]
   Google Scholar
• Miller PD, Civitelli R, Zaidi M, et al. Efficacy of intravenous ibandronate injections in postmenopausal osteoporosis: DIVA 2-year findings. International Society for Clinical Densitometry annual meeting. San Diego, CA, 1–4 February 2006
   Google Scholar